The fight that Mikhail Blagosklonny is putting up against Cancer
Cancer has been a menace to many for the past few decades. The biggest dream for the 21st century scientist and especially medical researchers is to figure out the exact cause of cancer and if possible, get a treatment for it. The fight has become a serious concern for many; governments are giving more funds to institutions that carry out cancer research and the FDA is working over time to look into the feasibility of the medicines and therapies being proposed to them. one of the people that have been in the frontline in looking for a suitable treatment for cancer is Mikhail Blagosklonny, an Oncology professor at the Roswell Park Cancer Institute located in New York.
Mikhail started his journey in medical research back in his home country of Russia. He attended the First Pavlov state Medical University and attained his MD and PhD in medicine and cardiology. The first job that he got when he arrived in the US was the post of an associate professor at the New York Medical College. This was followed by an appointment to the post of researcher at the Ordway Research Institute in Albany, New York. He got the appointment to his current job in 2008. His current research is mainly connected with aging and longevity, cancer cells and the therapies that can help in the protection of the healthy cells from getting the damages that are caused by cancer.
He has come up with a therapy that he believes will work in the treatment of cancer. This involves the use of Rampamycin, a medicine that has for a long time been used for the treatment of cancer, and especially on the patients in order to prolong their lives. He has been a very strong advocate for the use of the drug in cancer therapy. He has many articles published in journals and other publications about the same subject. He is currently an editor and contributing author for Aging Magazine, Cell Cycle magazine and Onctarget. The journal is peer reviewed and is published by Impact Journals. He contributes to the editorial board at Cell Death and Differentiation Magazine. He has many publications to his name and is working to see that human life is extended through the use of the right therapies.
Follow Oncotarget journal on Twitter.